Combination chemotherapy with Docetaxel, Cisplatin, and TS-1 for head and neck cancer

Bibliographic Information

Other Title
  • 頭頸部癌に対するドセタキセル、シスプラチン、TS-1併用療法の検討

Search this article

Description

We conducted the phase I study of the combination chemotherapy with Docetaxel (D), Cisplatin (C) and TS-1 (T) for head and neck cancer. D and C were administered at day 8 and T was orally administered from day 1 to day 14. The second course was started at day 29 except for NC cases. The dose of TS-1 was 80mg/m2/day for every levels. Six cases were enrolled for each level 1 (D: 30, C: 30mg/m2) and level 2 (D: 40, C: 30). DLT was defined as grade 4 hematological toxicity, grade 3 non-hematological toxicity, and more than 7 days delay of TS-1 administration. Two cases showed DLT at level 1 and 3 cases showed DLT, febrile neutropenia and dierrhea. The level 2 was considered MTD. The combination of D, C, and T seemed toxic. Adequate dose of D and C could not administered with the dose of T, 80mg/m2. We will again make assessment for the combination regimen with lower dose of T for higher dose of D and C in future.

Journal

  • OTOLOGIA FUKUOKA

    OTOLOGIA FUKUOKA 50 (5Supplement1), S14-S18, 2004

    JIBI TO RINSHO KAI

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top